Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 21, 2025; 31(31): 110481
Published online Aug 21, 2025. doi: 10.3748/wjg.v31.i31.110481
Skeletal muscle alterations in metabolic dysfunction-associated steatotic liver disease: A critical review of diagnostic, mechanistic, and therapeutic intersections
Vaynika Gupta, Ashwin Krishnamoorthy
Vaynika Gupta, College of Medicine and Health, University of Birmingham, Birmingham B15 2TT, United Kingdom
Ashwin Krishnamoorthy, Department of Upper GI Surgery, Queen Elizabeth Hospital Birmingham, Birmingham B15 2GW, United Kingdom
Author contributions: Gupta V wrote the original draft and completed editing; Krishnamoorthy A contributed to the conceptualization, reviewing and editing. All authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Vaynika Gupta, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom. vxg381@student.bham.ac.uk
Received: June 10, 2025
Revised: June 30, 2025
Accepted: July 25, 2025
Published online: August 21, 2025
Processing time: 72 Days and 13.9 Hours
Core Tip

Core Tip: Skeletal muscle alterations, such as sarcopenia, myosteatosis, and metabolic dysregulation, are increasingly common in pathogenesis and progression of metabolic dysfunction-associated steatotic liver disease. Underlying mechanisms, including insulin resistance, inflammation, and myokine imbalance, along with emerging biomarkers offer opportunities to study lifestyle and pharmacological interventions such as glucagon-like peptide-1 agonists. Further development must build on gaps in current literature, standardize diagnostic criteria and evaluate translational data for clinical applicability.